A THC Single-Cell Study Analyzed Nearly 16,000 Cells From Only Two People
A human THC experiment analyzed 15,973 immune cells, but those cells came from only two participants. The large cell count provided detailed molecular resolution; it did not make this a large clinical study or establish the frequency of an immune effect in the population.
Which specimens were studied?
Both participants were healthy 21-year-old men with prior cannabis exposure. Each received one intravenous THC dose of 0.03 mg/kg. Researchers isolated peripheral blood mononuclear cells before dosing and 70 minutes afterward, producing four biological sample collections.
Single-cell RNA sequencing measured gene expression in blood-derived immune cells. These were not brain cells, and the assay did not measure a THC concentration or directly test resistance to infection.
What changed at the molecular level
The analysis identified 294 genes meeting the study’s transcriptome-wide false-discovery-rate criterion. Sixty-nine were shared across at least two cell types, while 225 were cell-type specific. Results involved immune signaling, inflammation and cell-survival pathways.
No gene reached transcriptome-wide significance in dendritic cells; low cell numbers constrained that subgroup. A null result in such a sparse subgroup should not be read as proof that those cells are biologically unaffected.
Why thousands of cells do not supply thousands of independent people
Cells from the same participant share genetics, exposure and collection conditions. Before adjustment, cells clustered strongly by participant, illustrating the importance of individual variation. The investigators used a within-person design and statistical models to address that variation, but modeling cannot create additional independently exposed participants.
Follow-up PCR used material from the same blood samples. It supplied a second measurement approach, with incomplete agreement across genes and cell types, rather than an independent human replication.
Clinical implications remain exploratory
The findings generate hypotheses about acute immune regulation. They do not establish that THC causes a particular autoimmune disease, improves an inflammatory condition or produces a durable clinical immune deficit.
Intravenous administration, a single dose and one post-dose sampling time further limit transfer to smoking, edibles or chronic use. Any case-specific claim should identify the actual tissue, measured endpoint and independent participant count before translating a molecular signal into a health or impairment conclusion.
Related: Interpreting THC concentration and impairment.
Primary research
Single-cell Transcriptome Mapping Identifies Common and Cell-type Specific Genes Affected by Acute Delta9-tetrahydrocannabinol in Humans. DOI: 10.1038/s41598-020-59827-1.
